Researchers Identify Biomarker for Early Cognitive Decline in Parkinson

Share

(February 19, 2016) - Many patients with Parkinson's Disease (PD) develop mild cognitive impairment (MCI) or dementia. Identifying biomarkers for cognitive impairment could be instrumental in facilitating both early diagnosis of MCI and developing new cognitive-enhancing treatments. New research published in the Journal of Parkinson's Disease indicates that lower concentrations of ?-synuclein in cerebrospinal fluid (CSF) is associated with reduced performance on several cognitive tests.  Read more…

Click for a printer friendly version

Back to top